Meeting Posters

The effect of healthcare practitioner-participant interactions on participant heart rate during esketamine treatment (Abstract)

Deschamps
21st Annual Scientific Meeting

Comparison of the ten-item pediatric Positive and Negative Syndrome Scale (PANSS-10) to the PANSS-6 in an adult, acutely exacerbated clinical trial population with schizophrenia (Abstract)

Daniel
21st Annual Scientific Meeting

The patient and clinician reported circumplex model of depression (Abstract)

Cole
21st Annual Scientific Meeting

Enrichment based on speech latency enhances treatment effects in a Phase III study of brilaroxazine (Abstract)

Cohen
21st Annual Scientific Meeting

MedDRA coding conventions for describing unique psychoactive effects of empathogenic drugs (Abstract)

Beaster
21st Annual Scientific Meeting

Validation of a precision measure of cognitive change in a phase II clinical trial in early AD: The Early and Mild Alzheimer’s Cognitive Composite (EMACC) (Abstract)

Barnum
21st Annual Scientific Meeting

Ultra-low dose buprenorphine to sustain antidepressant and antisuicidal effects of intravenous ketamine in treatment-resistant depression with suicidal ideation: Protocol design and preliminary results from a randomized controlled trial (Abstract)

Bandeira
21st Annual Scientific Meeting

Preliminary development of the Assessment of Rapid Affect Change (ARAC): A novel measure for psychoplastogen response (Abstract)

Averill
21st Annual Scientific Meeting

Utility of negative symptom burden in predicting transition to psychosis among individuals at clinical high risk (Abstract)

Arnovitz
21st Annual Scientific Meeting

Analyzing referral influx patterns over a 24-hour period and the impact of timely responses on referral engagement in depression trials (Abstract)

Apter
21st Annual Scientific Meeting

Standardization of EEG enrichment marker acquisitions in a randomized, double-blind, placebo-controlled study of ALTO-300 in adults with major depression disorder (Abstract)

Anup
21st Annual Scientific Meeting

Translating animal models into clinical programs: The IRIS trial for investigational ML-004 in autism spectrum disorder (Abstract)

Abbs
21st Annual Scientific Meeting

Measurement of schizophrenia symptoms through speech phenotyping from PANSS recordings: a cross-study validation (Abstract)

Abbas
21st Annual Scientific Meeting

Enhancing speech analysis through de-hallucination and LLM diarization in physician-patient interviews (Abstract)

Tomioka
2024 Autumn Conference

Differences in detected error rate and resolution between clinical data validation and video review in Phase III clinical trials (Abstract)

Steele
2024 Autumn Conference

Reference ranges of healthy brain network activity to inform CNS treatment development (Abstract)

Setton
2024 Autumn Conference

Insights in psychedelic research – Historical overview (Abstract)

Rundle
2024 Autumn Conference

Evaluating psychotherapeutic components in psychedelic-assisted therapies: A comprehensive review (Abstract)

Price
2024 Autumn Conference

Development of a comprehensive guide for navigating information on digital biomarkers in CNS clinical trials (Abstract)

Pendergrass
2024 Autumn Conference

Analytical validation of a novel quality assurance approach for COAs in Alzheimer’s disease clinical trials (Abstract)

Newsome
2024 Autumn Conference